For attendees at a two-day regulatory workshop on strengthening antitrust enforcement in the pharma industry, the message couldn’t have been clearer: the days when megamergers could go on without too much scrutiny.
Then, almost as if to present a test case to antitrust officials, The Wall Street Journal reported two days later that New Jersey-based Merck & what. eyeing a purchase Seattle Area Biotech season Which is now worth just over $30 billion. The report said there may be other claimants and closing a deal “could be difficult given the increased risk of regulatory challenge.”